Phaseline

Companies › CellARTs

CellARTs: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cell Maturation–Phase 1Infertility, MaleDec 2026
Genetic Reprogramming–Phase 1Infertility, MaleDec 2026
Genetic Screening–Phase 1Infertility, MaleDec 2026
Stem cell–Phase 1Infertility, MaleDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06841861Stem cellPhase 1Infertility, MaleGenitourinaryDec 2026
NCT06841861Genetic ScreeningPhase 1Infertility, MaleGenitourinaryDec 2026
NCT06841861Genetic ReprogrammingPhase 1Infertility, MaleGenitourinaryDec 2026
NCT06841861Cell MaturationPhase 1Infertility, MaleGenitourinaryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.